KR20170020383A - Mic-1 융합 단백질 및 그것의 사용 - Google Patents

Mic-1 융합 단백질 및 그것의 사용 Download PDF

Info

Publication number
KR20170020383A
KR20170020383A KR1020167037059A KR20167037059A KR20170020383A KR 20170020383 A KR20170020383 A KR 20170020383A KR 1020167037059 A KR1020167037059 A KR 1020167037059A KR 20167037059 A KR20167037059 A KR 20167037059A KR 20170020383 A KR20170020383 A KR 20170020383A
Authority
KR
South Korea
Prior art keywords
seq
ala
mic
glu
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167037059A
Other languages
English (en)
Korean (ko)
Inventor
알란 크리스티안 셔
샤를로트 헬그스트란
미카엘 파올로 바스트너 산드리니
세바스티안 벡 요르겐센
헤닝 토거슨
크리스티안 사스-오룸
스벤 하스트루프
킴 빌바우어 안데르센
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20170020383A publication Critical patent/KR20170020383A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A61K47/48284—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020167037059A 2014-06-24 2015-06-17 Mic-1 융합 단백질 및 그것의 사용 Withdrawn KR20170020383A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14173664.5 2014-06-24
EP14173664 2014-06-24
PCT/EP2015/063596 WO2015197446A1 (en) 2014-06-24 2015-06-17 Mic-1 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
KR20170020383A true KR20170020383A (ko) 2017-02-22

Family

ID=51032955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167037059A Withdrawn KR20170020383A (ko) 2014-06-24 2015-06-17 Mic-1 융합 단백질 및 그것의 사용

Country Status (15)

Country Link
US (2) US9272019B2 (OSRAM)
EP (1) EP3160496B1 (OSRAM)
JP (1) JP6696915B2 (OSRAM)
KR (1) KR20170020383A (OSRAM)
CN (1) CN106459222A (OSRAM)
AR (1) AR100945A1 (OSRAM)
AU (1) AU2015279525A1 (OSRAM)
BR (1) BR112016029848A2 (OSRAM)
CA (1) CA2952293A1 (OSRAM)
IL (1) IL249327A0 (OSRAM)
MX (1) MX2016016063A (OSRAM)
RU (1) RU2017101436A (OSRAM)
TW (1) TW201613958A (OSRAM)
WO (1) WO2015197446A1 (OSRAM)
ZA (1) ZA201608214B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102195740B1 (ko) * 2020-03-25 2020-12-28 서울대학교산학협력단 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2021194257A1 (ko) * 2020-03-25 2021-09-30 (주) 업테라 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP6509852B2 (ja) 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CA3025251A1 (en) * 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
GB201615844D0 (en) * 2016-09-16 2016-11-02 Genagon Therapeutics Ab Agents for use in therapy
EP3551214B1 (en) * 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700553D0 (en) * 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
EP3612558A1 (en) 2017-04-20 2020-02-26 Novo Nordisk A/S Methods of purification of albumin fusion proteins
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019048660A1 (en) 2017-09-10 2019-03-14 Novo Nordisk A/S MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CA3096097A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3833974A2 (en) 2018-08-10 2021-06-16 Novartis AG Gfral extracellular domains and methods of use
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
AU2020394255A1 (en) * 2019-11-26 2022-06-09 Yuhan Corporation Long-acting GDF15 fusion protein and pharmaceutical composition comprising same
JP2023504208A (ja) * 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
MY209909A (en) * 2019-12-11 2025-08-11 Lg Chemical Ltd Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
WO2021133822A1 (en) * 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
CN116925237A (zh) * 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN115244076B (zh) * 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
CN112694520B (zh) * 2020-12-02 2023-01-17 图凌(杭州)生物医药有限公司 一种人工多肽hm、其抗体及在病理检测中的应用
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
JP2025505198A (ja) 2022-02-10 2025-02-21 ノバルティス アーゲー 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
ES2555956T3 (es) 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
PT1751184E (pt) * 2004-05-13 2009-11-10 Lilly Co Eli Proteínas de fusão de fgf-21
JP2008507292A (ja) * 2004-07-26 2008-03-13 アステリオン・リミテッド リンカー
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
JP6509852B2 (ja) 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102195740B1 (ko) * 2020-03-25 2020-12-28 서울대학교산학협력단 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2021194257A1 (ko) * 2020-03-25 2021-09-30 (주) 업테라 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템

Also Published As

Publication number Publication date
US20160129083A1 (en) 2016-05-12
TW201613958A (en) 2016-04-16
US9272019B2 (en) 2016-03-01
JP2017528419A (ja) 2017-09-28
AR100945A1 (es) 2016-11-09
RU2017101436A (ru) 2018-07-24
RU2017101436A3 (OSRAM) 2019-02-13
EP3160496B1 (en) 2021-03-03
WO2015197446A1 (en) 2015-12-30
US9956264B2 (en) 2018-05-01
IL249327A0 (en) 2017-02-28
JP6696915B2 (ja) 2020-05-20
AU2015279525A1 (en) 2016-12-15
EP3160496A1 (en) 2017-05-03
US20160015784A1 (en) 2016-01-21
BR112016029848A2 (pt) 2017-10-24
CN106459222A (zh) 2017-02-22
CA2952293A1 (en) 2015-12-30
ZA201608214B (en) 2018-11-28
MX2016016063A (es) 2017-03-10

Similar Documents

Publication Publication Date Title
KR20170020383A (ko) Mic-1 융합 단백질 및 그것의 사용
US12006344B2 (en) MIC-1 compounds and use thereof
KR102085605B1 (ko) 대사 장애를 치료하기 위한 융합 단백질
EP2858662B1 (en) Fibroblast growth factor 21 proteins
US8809499B2 (en) Fusion protein of human fibroblast growth factor-21 and exendin-4
EP2468858B1 (en) Fusion protein regulating plasma glucose and lipid, its preparation method and use
KR20130115305A (ko) Fgf21-연관 장애의 치료 방법
WO2018011803A1 (en) Fusion proteins with extended serum half life
US20170334971A1 (en) Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
KR20240126875A (ko) Glp-1과 gdf15의 융합 단백질 및 이의 용도
RU2776529C2 (ru) Соединения mic-1 и их применение
HK1235013A1 (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/ glucagon dual agonist

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20190904

WITB Written withdrawal of application